ArticleFrontiers in medicine2025
Clinical characteristics, management, and prognostic outcomes of ipilimumab-induced nephritis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ipilimumab-induced nephritis is a rare but potentially severe immune-related adverse event with incompletely defined clinical features and outcomes. This study aimed to synthesize its clinical presentation, pathology, management, and prognosis to facilitate timely recognition and evidence-based care. Methods: We identified cases of ipilimumab-induced nephritis from 28 published articles up to May 31, 2025, and abstracted individual patient-level data for descriptive analysis. Results: A total of 30 patients were included (26 male, 4 female; median age 63 years [range: 43, 78]). The median onset of nephritis following ipilimumab initiation was 7 weeks (range: 1, 48 weeks). Clinically, patients commonly presented with fatigue (26.7%), fever (20.0%), rash (13.3%), and weight loss (13.3%). Laboratory findings included elevated serum creatinine (median 3.4 mg/dL, range: 1.6, 10.4), eosinophilia (18.5%), proteinuria (14.8%), urinary tract infection (11.1%), increased C-reactive protein (7.4%), and neutrophilic leukocytosis (3.7%). Histopathological analysis revealed acute tubulointerstitial nephritis in 87.5% of cases, followed by IgA nephropathy (12.5%), and interstitial edema (4.2%). The cornerstone of treatment was immediate discontinuation of ipilimumab, coupled with systemic corticosteroids. In select cases, immunosuppressive agents (e.g., mycophenolate mofetil, infliximab, cyclophosphamide) or renal replacement therapies (hemodialysis, plasma exchange) were utilized, though their efficacy requires further validation. Clinical improvement was observed in 93.3% of patients, with a median recovery time of 7 weeks (range: 1, 36 weeks), while 3.3% experienced fatal outcomes. Conclusion: These findings underscore the importance of early recognition and prompt intervention. A thorough clinical evaluation, including symptom assessment, physical examination, and laboratory testing, is essential for accurate diagnosis. Corticosteroids remain the mainstay of therapy, and early drug withdrawal is critical in mitigating renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.